Immunome Newsroom

Immunome Analyst Ratings

BenzingaMay 31 06:00 ET

Immunome's Promising Pipeline and Strategic Positioning Affirm Buy Rating

TipRanksMay 16 04:21 ET

TD Cowen Sticks to Their Buy Rating for Immunome (IMNM)

TipRanksMay 13 08:10 ET

Immunome Analyst Ratings

BenzingaApr 30 08:47 ET

JPMorgan Starts Immunome With Overweight Rating, $24 Price Target

MT NewswiresApr 30 07:31 ET

Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)

TipRanksApr 30 05:05 ET

Immunome Analyst Ratings

BenzingaApr 15 06:34 ET

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)

TipRanksApr 8 03:58 ET

Immunome Analyst Ratings

BenzingaApr 1 08:01 ET

Immunome (IMNM) Receives a Buy From Wedbush

TipRanksApr 1 08:01 ET

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM)

TipRanksMar 29 03:25 ET

TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)

TipRanksMar 28 17:40 ET

Leerink Partners Sticks to Their Buy Rating for Immunome (IMNM)

TipRanksFeb 22 00:18 ET

Immunome Analyst Ratings

BenzingaJan 23 07:59 ET

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Immunome (IMNM) and Simulations Plus (SLP)

TipRanksJan 4 06:00 ET

Immunome Analyst Ratings

BenzingaDec 19, 2023 07:39 ET

Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies

MT NewswiresDec 19, 2023 07:15 ET

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Spruce Biosciences (SPRB) and Immunome (IMNM)

TipRanksMar 20, 2023 12:35 ET

Cantor Fitzgerald Reiterates Overweight on Immunome, Maintains $8 Price Target

BenzingaMar 20, 2023 08:24 ET

Chardan Capital Sticks to Its Buy Rating for Immunome (IMNM)

TipRanksMar 17, 2023 08:31 ET